{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:24:16Z","timestamp":1790821456986,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bulcan.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T17:14:45Z","timestamp":1691687685000},"page":"1063-1083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recommandations du r\u00e9seau national ENDOCAN-COMETE pour la prise en charge des ph\u00e9ochromocytomes et paragangliomes m\u00e9tastatiques"],"prefix":"10.1016","volume":"110","author":[{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Haissaguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Decaussin-Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Renaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Miralli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Murez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pattou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Henri","family":"Savoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Paule","family":"Gimenez-Roqueplo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Lib\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.06.002_bib0380","doi-asserted-by":"crossref","first-page":"L21","DOI":"10.1530\/EJE-21-0258","article-title":"Incidence of pheochromocytoma and paraganglioma varies according to altitude: meta-regression analysis","volume":"184","author":"Leung","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0385","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0390","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jso.24063","article-title":"Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: a single institution experience","volume":"112","author":"Choi","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0395","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272\u00a0patients over 55\u00a0years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0400","series-title":"WHO classification of tumours of endocrine organs","first-page":"179","year":"201710"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0405","doi-asserted-by":"crossref","first-page":"e0216658","DOI":"10.1371\/journal.pone.0216658","article-title":"EUS-guided tissue acquisition in the study of the adrenal glands: results of a nationwide multicenter study","volume":"14","author":"Martin-Cardona","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0410","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/dc.24261","article-title":"Fine-needle aspiration of adrenal lesions: a 20-year single institution experience with comparison of percutaneous and endoscopic ultrasound guided approaches","volume":"47","author":"Novotny","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0415","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/00365521.2013.799222","article-title":"Multicenter randomized controlled trial comparing the performance of 22\u00a0gauge versus 25\u00a0gauge EUS-FNA needles in solid masses","volume":"48","author":"Vilmann","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0420","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022\u00a0WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0425","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0435","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/cancers11020225","article-title":"The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-a meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0440","doi-asserted-by":"crossref","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0445","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12022-018-9555-2","article-title":"The role of immunohistochemistry and molecular analysis of succinate dehydrogenase in the diagnosis of endocrine and non-endocrine tumors and related syndromes","volume":"30","author":"Oudijk","year":"2019","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0450","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0455","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41379-019-0343-4","article-title":"Carbonic anhydrase 9\u00a0immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma\u00a0\u2013\u00a0a retrospective and prospective study","volume":"33","author":"Favier","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0460","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1210\/clinem\/dgab202","article-title":"Recurrence-free survival analysis in locally advanced pheochromocytoma: first appraisal","volume":"106","author":"Moog","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0465","doi-asserted-by":"crossref","first-page":"684668","DOI":"10.3389\/fendo.2021.684668","article-title":"Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with malignant pheochromocytoma and paraganglioma","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0470","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): a European Network for the Study of Adrenal Tumors Retrospective Study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0475","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0480","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s00330-015-4024-5","article-title":"The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators","volume":"26","author":"Gravel","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0485","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12880-016-0114-3","article-title":"Head and neck paragangliomas: diffusion weighted and dynamic contrast enhanced magnetic resonance imaging characteristics","volume":"16","author":"Yuan","year":"2016","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0490","first-page":"863","article-title":"Head and neck paragangliomas: improved tumor detection using contrast-enhanced 3D time-of-flight MR angiography as compared with fat-suppressed MR imaging techniques","volume":"25","author":"van den Berg","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0495","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019\u00a0for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0500","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"Fonte","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0505","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0510","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"NGS in PPGL (NGSnPPGL) Study Group","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0515","doi-asserted-by":"crossref","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20\u00a0years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0520","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1507\/endocrj.EJ17-0276","article-title":"Efficacy and safety of metyrosine in pheochromocytoma\/paraganglioma: a multi-center trial in Japan","volume":"65","author":"Naruse","year":"2018","journal-title":"Endocr J"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0525","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/j.jviscsurg.2011.07.003","article-title":"Pheochromocytoma and abdominal paraganglioma","volume":"148","author":"Renard","year":"2011","journal-title":"J Visc Surg"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0530","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jss.2019.05.042","article-title":"Conversion during laparoscopic adrenalectomy for pheochromocytoma: a cohort study in 244\u00a0patients","volume":"243","author":"Schweitzer","year":"2019","journal-title":"J Surg Res"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0535","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0540","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1002\/bjs.11348","article-title":"Meta-analysis of \u03b1-blockade versus no blockade before adrenalectomy for phaeochromocytoma","volume":"107","author":"Schimmack","year":"2020","journal-title":"Br J Surg"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0545","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12893-020-00824-6","article-title":"Laparoscopic versus open surgery for pheochromocytoma: a meta-analysis","volume":"20","author":"Fu","year":"2020","journal-title":"BMC Surg"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0550","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/bjs.10744","article-title":"Extent of surgery for phaeochromocytomas in the genomic era","volume":"105","author":"Rossitti","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0555","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","article-title":"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","volume":"15","author":"Castinetti","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2023.06.002_bib0560","doi-asserted-by":"crossref","first-page":"R177","DOI":"10.1016\/j.purol.2019.01.011","article-title":"[French ccAFU guidelines\u00a0\u2013\u00a0update 2018\u20132020: adrenal cancer]","volume":"28","author":"Savoie","year":"2018","journal-title":"Prog Urol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0565","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.wneu.2022.11.037","article-title":"Modern management of complex tympanojugular paragangliomas: a systematic review and meta-analysis","volume":"170","author":"Dharnipragada","year":"2023","journal-title":"World Neurosurg"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0570","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0575","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","article-title":"Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series","volume":"24","author":"Strajina","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0580","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0585","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","article-title":"Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma","volume":"59","author":"Gravel","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0590","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.3390\/cancers11020195","article-title":"Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma","volume":"11","author":"Kohlenberg","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0595","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00270-019-02314-6","article-title":"Preventive vertebroplasty for long-term consolidation of vertebral metastases","volume":"42","author":"Delpla","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0600","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1148\/radiol.2018181105","article-title":"Fluoroscopy and cone-beam CT-guided fixation by internal cemented screw for pathologic pelvic fractures","volume":"290","author":"Roux","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0645","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/1097-0142(19951015)76:8<1476::AID-CNCR2820760827>3.0.CO;2-9","article-title":"A 15-year experience with chemotherapy of patients with paraganglioma","volume":"76","author":"Patel","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0635","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18\u00a0patients","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0640","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0630","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0650","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","article-title":"Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas","volume":"8","author":"Asai","year":"2017","journal-title":"Horm Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0660","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0665","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918763367","article-title":"Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0655","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0710","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2\u00a0trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0715","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1016\/j.annonc.2021.08.702","article-title":"567O First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0700","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0705","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/jco.2015.33.7_suppl.457","article-title":"Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P\/PG): preliminary results","volume":"33","author":"Burotto Pichun","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0725","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2\u00a0study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0620","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0625","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0610","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0615","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0730","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12672-017-0303-8","article-title":"Interferon-alpha treatment for disease control in metastatic pheochromocytoma\/paraganglioma patients","volume":"8","author":"Hadoux","year":"2017","journal-title":"Horm Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0735","doi-asserted-by":"crossref","first-page":"e000347","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0740","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"Pheochromocytoma: recommendations for clinical practice from the First International Symposium, October 2005","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0670","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0675","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2013.233","article-title":"Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas","volume":"27","author":"Cassol","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0680","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma","volume":"94","author":"Joshua","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0685","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors","volume":"94","author":"Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0690","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0695","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/15384047.2018.1470732","article-title":"A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease","volume":"19","author":"Yuan","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0720","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0745","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1016\/j.annonc.2022.07.023","article-title":"2MO EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma\/paraganglioma (MPP): phase I\/II SPENCER study","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.06.002_bib0375","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:11Z","timestamp":1757792291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0007455123002977"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.06.002","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations du r\u00e9seau national ENDOCAN-COMETE pour la prise en charge des ph\u00e9ochromocytomes et paragangliomes m\u00e9tastatiques","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}